← Back to patent-cliff list
RBM 39 targeting therapeutic (Recursion Pharmaceuticals)
Tier C — Watch / tradeRBM 39 targeting therapeutic (Recursion Pharmaceuticals)
Recursion Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：RBM39
Indications (approved)：Lymphoma, Solid tumour, Ovarian cancer
Regional status
US
Phase II
2024-10-02
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of RBM 39 targeting therapeutic (Recursion Pharmaceuticals)?
Approved indications include: Lymphoma, Solid tumour, Ovarian cancer.
When does the RBM 39 targeting therapeutic (Recursion Pharmaceuticals) patent expire?
No public expiry year is available for RBM 39 targeting therapeutic (Recursion Pharmaceuticals) yet; this page updates once verified.
How do I get a quote for RBM 39 targeting therapeutic (Recursion Pharmaceuticals) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01